文献速递腹部技术与安全MR

基于对比剂类型的MRI对局部区域治疗后肝细胞癌残留或复发的诊断效能:系统评价与Meta分析

Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.
PubMed 文献 · Abdom Radiol (NY) · 2024-01-10

该系统评价与Meta分析纳入15项研究共803例患者和1018个病灶,比较细胞外对比剂MRI(ECA-MRI)与肝细胞特异性对比剂MRI(EOB-MRI)对局部区域治疗后肝细胞癌残留或复发的诊断效能。结果显示ECA-MRI与EOB-MRI的汇总敏感度(87% vs. 79%)和特异度(92% vs. 96%)无显著差异(P=0.41),HSROC曲线下面积分别为0.95和0.92,亚组分析各变量下均无显著差异(均P>0.05)。

要点

  • ECA-MRI与EOB-MRI检测局部区域治疗后HCC残留或复发的汇总敏感度87% vs. 79%、特异度92% vs. 96%,无显著差异(P=0.41)。
  • HSROC曲线下面积ECA-MRI为0.95、EOB-MRI为0.92,诊断效能总体相当。
  • 亚组分析(研究设计、LRT类型、病因、基线病灶大小、检查时间、场强)均未见两种对比剂诊断效能显著差异(均P>0.05)。

核心结论

  • ECA-MRI在评估局部区域治疗后HCC残留或复发方面总体诊断效能与EOB-MRI相当。

研究设计与样本

  • 系统评价与Meta分析,纳入15项原始研究,共803例患者和1018个病灶;检索PubMed、EMBASE、Cochrane Library和Web of Science数据库。

诊断标准与关键数值

  • ECA-MRI检测局部区域治疗后HCC残留或复发的汇总敏感度为87%,EOB-MRI为79%。
  • ECA-MRI检测局部区域治疗后HCC残留或复发的汇总特异度为92%,EOB-MRI为96%。
  • ECA-MRI与EOB-MRI的汇总敏感度和特异度差异无统计学意义(P=0.41)。
  • HSROC曲线下面积ECA-MRI为0.95,EOB-MRI为0.92。
  • 亚组分析按研究设计、LRT类型、肝病最常见病因、基线病灶大小、治疗后检查时间和MRI场强分组,两种对比剂诊断效能均无显著差异(均P>0.05)。

临床应用与阅片要点

  • 作者结论认为,ECA-MRI在评估局部区域治疗后HCC残留或复发方面总体诊断效能与EOB-MRI相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The ideal contrast agent for imaging patients with hepatocellular carcinoma (HCC) following locoregional therapies (LRT) remains uncertain. We conducted a meta-analysis to assess the diagnostic performance of magnetic resonance imaging with extracellular contrast agent (ECA-MRI) and hepatobiliary agent (EOB-MRI) in detecting residual or recurrence HCC following LRT.

METHODS: Original studies comparing the diagnostic performance of ECA-MRI and EOB-MRI were systematically identified through comprehensive searches in PubMed, EMBASE, Cochrane Library and Web of Science databases. The pooled sensitivity and specificity of ECA-MRI and EOB-MRI were calculated using a bivariate-random-effects model. Subgroup-analyses were conducted to compare the diagnostic performance of ECA-MRI and EOB-MRI according to different variables. Meta-regression analysis was employed to explore potential sources of study heterogeneity.

RESULTS: A total of 15 eligible studies encompassing 803 patients and 1018 lesions were included. Comparative analysis revealed no significant difference between ECA-MRI and EOB-MRI in the overall pooled sensitivity (87% vs. 79%) and specificity (92% vs. 96%) for the detection of residual or recurrent HCC after LRT (P = 0.41), with comparable areas under the HSROC of 0.95 and 0.92. Subgroup analyses indicated no significant diagnostic performance differences between ECA-MRI and EOB-MRI according to study design, type of LRT, most common etiology of liver disease, baseline lesion size, time of post-treated examination and MRI field strength (All P > 0.05).

CONCLUSION: ECA-MRI exhibited overall comparable diagnostic performance to EOB-MRI in assessing residual or recurrent HCC after LRT.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Zhou S, Wang S, Xiang J, et al. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis. Abdom Radiol (NY). 2024. PMID: 38200213. doi:10.1007/s00261-023-04143-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。